Search Follow us


Following the positive Phase IIb trial results with universal flu vaccine, M-001, BiondVax is now preparing to initiate a Phase III study, which will likely evaluate M-001 as a universal, standalone vaccine – another major strategic decision by BiondVax – as opposed to a stepwise approach to develop M-001 as a primer and then as a standalone vaccine. A universal, standalone flu vaccine indication is the most lucrative and the pivotal trial could start in 2018. We increase our valuation of BiondVax to $165m (NIS577m), $26.8/ADS (NIS2.34/share), from $111m previously.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs